152 related articles for article (PubMed ID: 28099210)
61. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
62. Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Papadopoulos S; Koulouris P; Royer-Chardon C; Tsoumakidou G; Dolcan A; Cherix S; Matter M; Omoumi P; Digklia A
Front Endocrinol (Lausanne); 2022; 13():794512. PubMed ID: 35399933
[TBL] [Abstract][Full Text] [Related]
63. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
64. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
[TBL] [Abstract][Full Text] [Related]
65. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
Sabath B; Muhammad HA; Balagani A; Ost DE; Vakil E; Ahmed T; Vial MR; Grosu HB
BMC Cancer; 2018 Oct; 18(1):937. PubMed ID: 30285733
[TBL] [Abstract][Full Text] [Related]
66. Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.
Harris BHL; Walsh JL; Neciunaite R; Manders P; Cooper A; De Souza P
Clin Exp Dermatol; 2018 Mar; 43(2):234-236. PubMed ID: 29282751
[No Abstract] [Full Text] [Related]
67. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Sideras K; Menefee ME; Burton JK; Erlichman C; Bible KC; Ivy SP
J Clin Oncol; 2010 Jul; 28(19):e312-3. PubMed ID: 20516434
[No Abstract] [Full Text] [Related]
68. Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option.
Sari M
J Cancer Res Ther; 2020; 16(4):900-902. PubMed ID: 32930137
[TBL] [Abstract][Full Text] [Related]
69. Rapid hair depigmentation in patient treated with pazopanib.
Šeparović R; Pavlović M; Silovski T; Tečić Vuger A
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30139781
[TBL] [Abstract][Full Text] [Related]
70. [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Penel N; Ryckewaert T; Orbach D
Bull Cancer; 2020 Mar; 107(3):375-380. PubMed ID: 31812284
[TBL] [Abstract][Full Text] [Related]
71. Active surveillance and emerging medical treatment options for desmoid: when and for whom?
Bonvalot S; Miah A; Kasper B
Curr Opin Oncol; 2024 Jul; 36(4):263-268. PubMed ID: 38726846
[TBL] [Abstract][Full Text] [Related]
72. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
73. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience.
Maruzzo M; Martin-Liberal J; Messiou C; Miah A; Thway K; Alvarado R; Judson I; Benson C
Clin Sarcoma Res; 2015; 5():5. PubMed ID: 25664166
[TBL] [Abstract][Full Text] [Related]
74. Clinical trials in desmoid-type fibromatosis in children and adults: A systematic review.
van Maren SA; van Noesel MM; Husson O; van der Graaf WTA
Pediatr Blood Cancer; 2022 Sep; 69(9):e29831. PubMed ID: 35714333
[TBL] [Abstract][Full Text] [Related]
75. Pazopanib for progressive desmoid tumours: children, persistant effects, and cost.
Nishida Y; Sakai T; Koike H; Ito K
Lancet Oncol; 2019 Oct; 20(10):e555. PubMed ID: 31578997
[No Abstract] [Full Text] [Related]
76. Pazopanib for progressive desmoid tumours: children, persistant effects, and cost - Author's reply.
Italiano A
Lancet Oncol; 2019 Oct; 20(10):e556. PubMed ID: 31578998
[No Abstract] [Full Text] [Related]
77. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
Wang Z; Wu J; Tian X; Hao C
Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
[TBL] [Abstract][Full Text] [Related]
78. Aggressive fibromatosis: evidence for a stable phase.
Mitchell G; Thomas JM; Harmer CL
Sarcoma; 1998; 2(3-4):149-54. PubMed ID: 18521247
[TBL] [Abstract][Full Text] [Related]
79. Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management.
Penel N; Ryckewaert T; Le Deley MC
Am J Clin Oncol; 2019 Dec; 42(12):958. PubMed ID: 31764064
[No Abstract] [Full Text] [Related]
80. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Libertini M; Mitra I; van der Graaf WTA; Miah AB; Judson I; Jones RL; Thomas K; Moskovic E; Szucs Z; Benson C; Messiou C
Clin Sarcoma Res; 2018; 8():13. PubMed ID: 29785261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
